Advertisement
"Lilly has a growing and exciting diabetes and obesity R&D portfolio thatdemands exceptional clinical leadership to guide and successfully develop,"said Vince Mihalik, Vice President and Global Brand Development PlatformLeader, Diabetes, Obesity and Endocrine. "Robert is widely recognized andrespected in the diabetes community for his scientific and clinical excellenceand his considerable leadership abilities. He'll be a fantastic addition tothe Lilly team."
Advertisement
Heine is currently professor of diabetology in the Department ofEndocrinology and director of the Diabetes Centre at the VU (VrijeUniversiteit) University Medical Center in Amsterdam, Netherlands. In additionto involvement in several research projects, Heine holds positions within theEuropean Association for the Study of Diabetes (EASD), the European Foundationfor the Study of Diabetes (EFSD) and the American Diabetes Association (ADA),including chair of the EASD subcommittee for Clinical Research Training,president of the organizing committee for the 2007 EASD annual meeting, and amember of the ADA Expert Committee on guidelines for the treatment ofhyperglycemia in type 2 diabetes. He is a prolific author, with more than 350published papers, and currently serves as associate editor of DiabeticMedicine and an editorial board member for several other publications. Heine'sprimary research interests include the epidemiology and pathophysiology oftype 2 diabetes.
"We couldn't be more pleased that Dr. Heine has decided to bring hisconsiderable talents to Lilly," said David Moller, M.D., Vice President,Endocrine and Cardiovascular Research and Clinical Investigation, LillyResearch Laboratories. "Robert's outstanding clinical experience and depth ofscientific expertise will be a major contributor to the sustained leadershipof Lilly in diabetes and related metabolic disorders as we continue to bringnovel medicines to patients in need around the world."
"It's a privilege to join a team with such an impressive history ofinnovation and one that is also shaping the future of diabetes care," saidHeine. "I'm excited for the opportunity to work in a new and dynamicatmosphere at Lilly with a group of truly talented scientists."
About Lilly
Lilly, a leading innovation-driven corporation, is developing a growingportfolio of first-in-class and best-in-class pharmaceutical products byapplying the latest research from its own worldwide laboratories and fromcollaborations with eminent scientific organizations. Headquartered inIndianapolis, Ind., Lilly provides answers -- through medicines andinformation -- for some of the world's most urgent medical needs. Additionalinformation about Lilly is available at www.lilly.com.
C-LLY
(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )
SOURCE Eli Lilly and Company
